AZN vs. MA: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AZN and MA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
AZN trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, MA is a standard domestic listing.
| Symbol | AZN | MA |
|---|---|---|
| Company Name | AstraZeneca PLC | Mastercard Incorporated |
| Country | United Kingdom | United States |
| GICS Sector | Health Care | Financials |
| GICS Industry | Pharmaceuticals | Financial Services |
| Market Capitalization | 247.43 billion USD | 536.27 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | May 12, 1993 | May 25, 2006 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of AZN and MA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | AZN | MA |
|---|---|---|
| 5-Day Price Return | 1.96% | 1.32% |
| 13-Week Price Return | 14.68% | 4.05% |
| 26-Week Price Return | 2.26% | 4.35% |
| 52-Week Price Return | -9.33% | 26.53% |
| Month-to-Date Return | 5.69% | 4.72% |
| Year-to-Date Return | 14.33% | 12.66% |
| 10-Day Avg. Volume | 0.98M | 2.36M |
| 3-Month Avg. Volume | 1.47M | 2.68M |
| 3-Month Volatility | 22.26% | 21.33% |
| Beta | 1.01 | 0.99 |
Profitability
Return on Equity (TTM)
AZN
19.84%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
AZN’s Return on Equity of 19.84% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
MA
191.02%
Financial Services Industry
- Max
- 40.58%
- Q3
- 20.06%
- Median
- 10.67%
- Q1
- 4.19%
- Min
- -10.31%
MA’s Return on Equity of 191.02% is exceptionally high, placing it well beyond the typical range for the Financial Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
AZN
14.68%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
AZN’s Net Profit Margin of 14.68% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
MA
44.93%
Financial Services Industry
- Max
- 52.86%
- Q3
- 25.58%
- Median
- 12.23%
- Q1
- 6.64%
- Min
- -9.92%
A Net Profit Margin of 44.93% places MA in the upper quartile for the Financial Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
AZN
20.04%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
AZN’s Operating Profit Margin of 20.04% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
MA
55.78%
Financial Services Industry
- Max
- 77.28%
- Q3
- 37.68%
- Median
- 18.17%
- Q1
- 9.27%
- Min
- -8.19%
An Operating Profit Margin of 55.78% places MA in the upper quartile for the Financial Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | AZN | MA |
|---|---|---|
| Return on Equity (TTM) | 19.84% | 191.02% |
| Return on Assets (TTM) | 7.76% | 27.84% |
| Net Profit Margin (TTM) | 14.68% | 44.93% |
| Operating Profit Margin (TTM) | 20.04% | 55.78% |
| Gross Profit Margin (TTM) | 82.07% | -- |
Financial Strength
Current Ratio (MRQ)
AZN
0.86
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
AZN’s Current Ratio of 0.86 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
MA
1.16
Financial Services Industry
- Max
- 4.58
- Q3
- 2.59
- Median
- 1.33
- Q1
- 0.69
- Min
- 0.01
For the Financial Services industry, the Current Ratio is often not the most suitable measure of short-term liquidity.
Debt-to-Equity Ratio (MRQ)
AZN
0.73
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
AZN’s Debt-to-Equity Ratio of 0.73 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
MA
2.42
Financial Services Industry
- Max
- 4.96
- Q3
- 2.10
- Median
- 0.57
- Q1
- 0.12
- Min
- 0.00
The Debt-to-Equity Ratio is often not the primary focus for assessing leverage in the Financial Services industry.
Interest Coverage Ratio (TTM)
AZN
9.51
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
AZN’s Interest Coverage Ratio of 9.51 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
MA
37.93
Financial Services Industry
- Max
- 136.23
- Q3
- 56.08
- Median
- 6.55
- Q1
- 2.01
- Min
- -33.27
The Interest Coverage Ratio is often not a primary indicator of debt servicing capacity in the Financial Services industry.
Financial Strength at a Glance
| Symbol | AZN | MA |
|---|---|---|
| Current Ratio (MRQ) | 0.86 | 1.16 |
| Quick Ratio (MRQ) | 0.67 | 1.16 |
| Debt-to-Equity Ratio (MRQ) | 0.73 | 2.42 |
| Interest Coverage Ratio (TTM) | 9.51 | 37.93 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
AZN
2.00%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
AZN’s Dividend Yield of 2.00% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
MA
0.49%
Financial Services Industry
- Max
- 8.18%
- Q3
- 3.60%
- Median
- 1.56%
- Q1
- 0.00%
- Min
- 0.00%
MA’s Dividend Yield of 0.49% is consistent with its peers in the Financial Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
AZN
59.51%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
AZN’s Dividend Payout Ratio of 59.51% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
MA
19.15%
Financial Services Industry
- Max
- 155.56%
- Q3
- 63.71%
- Median
- 18.08%
- Q1
- 0.00%
- Min
- 0.00%
MA’s Dividend Payout Ratio of 19.15% is within the typical range for the Financial Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | AZN | MA |
|---|---|---|
| Dividend Yield (TTM) | 2.00% | 0.49% |
| Dividend Payout Ratio (TTM) | 59.51% | 19.15% |
Valuation
Price-to-Earnings Ratio (TTM)
AZN
29.72
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
A P/E Ratio of 29.72 places AZN in the upper quartile for the Pharmaceuticals industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
MA
39.22
Financial Services Industry
- Max
- 63.23
- Q3
- 32.10
- Median
- 14.41
- Q1
- 10.81
- Min
- 0.37
A P/E Ratio of 39.22 places MA in the upper quartile for the Financial Services industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
Price-to-Sales Ratio (TTM)
AZN
4.36
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
AZN’s P/S Ratio of 4.36 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
MA
17.62
Financial Services Industry
- Max
- 11.16
- Q3
- 5.45
- Median
- 2.61
- Q1
- 1.25
- Min
- 0.04
The P/S Ratio is often not a primary valuation tool in the Financial Services industry.
Price-to-Book Ratio (MRQ)
AZN
4.74
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
AZN’s P/B Ratio of 4.74 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
MA
64.98
Financial Services Industry
- Max
- 7.09
- Q3
- 3.79
- Median
- 1.46
- Q1
- 0.83
- Min
- 0.04
At 64.98, MA’s P/B Ratio is at an extreme premium to the Financial Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | AZN | MA |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 29.72 | 39.22 |
| Price-to-Sales Ratio (TTM) | 4.36 | 17.62 |
| Price-to-Book Ratio (MRQ) | 4.74 | 64.98 |
| Price-to-Free Cash Flow Ratio (TTM) | 30.13 | 33.58 |